D'ADDA, Mariella
 Distribuzione geografica
Continente #
NA - Nord America 174
EU - Europa 110
AS - Asia 66
OC - Oceania 1
SA - Sud America 1
Totale 352
Nazione #
US - Stati Uniti d'America 173
CN - Cina 55
IE - Irlanda 23
SE - Svezia 22
FR - Francia 20
GB - Regno Unito 16
DE - Germania 11
IT - Italia 9
KR - Corea 8
VN - Vietnam 3
FI - Finlandia 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
ES - Italia 1
HU - Ungheria 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
Totale 352
Città #
Chandler 73
Dublin 23
Beijing 22
Southend 13
Lawrence 9
Princeton 9
Sindelfingen 9
Seoul 8
Jinan 6
Wilmington 6
Falls Church 4
Los Angeles 4
Zhengzhou 4
Norwalk 3
Shenyang 3
Ashburn 2
Chengdu 2
Florence 2
Helsinki 2
New York 2
Ningbo 2
Redmond 2
Shanghai 2
Taizhou 2
Tianjin 2
Ann Arbor 1
Brasov 1
Brescia 1
Buenos Aires 1
Chicago 1
Dong Ket 1
Edinburgh 1
Fairfield 1
Guadalajara 1
Guangzhou 1
Haikou 1
Houston 1
Jacksonville 1
Jiaxing 1
Kent 1
Lanzhou 1
London 1
Melbourne 1
Milan 1
Nanjing 1
Newark 1
San Francisco 1
Seattle 1
Sopron 1
Taiyuan 1
Verona 1
Warsaw 1
Totale 243
Nome #
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 50
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 49
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 48
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 43
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 43
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 39
BCR}-{ABL}1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by {NGS 36
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 32
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 26
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 1
Totale 367
Categoria #
all - tutte 1.745
article - articoli 1.745
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.490


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202042 0 0 0 0 0 0 0 0 0 25 9 8
2020/202136 8 7 0 2 9 3 0 0 1 1 1 4
2021/202248 2 11 3 3 2 2 0 4 5 0 2 14
2022/2023188 9 20 15 21 24 50 0 15 22 2 7 3
2023/202453 3 6 2 12 0 7 1 1 0 17 4 0
Totale 367